BioCopy Advances AI Driven Cancer Therapies with Strategic Investment from Haute Capital

Basel 16 March 2026
As part of a Series A financing round scheduled to close on March 31, 2026, Haute Capital Partners has made a strategic investment in BioCopy, reflecting their confidence in BioCopy’s AI-powered drug development platform, particularly the advanced lung cancer drug candidate.

BioCopy AG, based in Basel, Switzerland, is transforming cancer drug discovery by combining artificial intelligence, automation, and precision screening technologies. The company targets previously unaddressable intracellular cancer mechanisms through peptide HLA biology, creating new antibody therapies for patients who currently have no treatment options. Central to BioCopy’s approach is its AI powered ValidaTe® platform, which profiles next generation anti-cancer candidates across thousands of cell targets. This pHLA focused system identifies the most promising candidates early, improving efficacy and safety while reducing the risk of later stage failures. A strong intellectual property portfolio, including granted patents on ultra-high throughput screening technologies and pending applications for novel drug candidates, targets, and AI based predictive tools underpin BioCopy’s research strategy and competitive edge.

The company is advancing five antibody programs across solid tumors including lung, ovarian, bladder, liver, and breast cancers. The lead lung cancer program is progressing toward IND readiness in 2027, a key step toward clinical development.

“ValidaTe allows us to develop the most effective and safest drugs against intracellular cancer targets, with AI driven precision,” said Dr. Matthias Wiedenfels, CEO of BioCopy AG. “The support from Haute Capital strengthens our ability to advance our portfolio toward more IND ready multi-specific drug candidates while continuing to explore previously untapped cancer targets. This investment underscores the strategic potential of our platform and our mission to bring effective therapies of utmost safety to patients who currently have no treatment options.”